Drug Profile
KIT 301
Alternative Names: KIT-301Latest Information Update: 15 Dec 2020
Price :
$50
*
At a glance
- Originator Kitov Pharmaceuticals
- Developer Purple Biotech
- Class Antihypertensives; Antirheumatics; Dihydropyridines; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension; Pain
Most Recent Events
- 10 Dec 2020 Kitov Pharmaceuticals is now called Purple Biotech
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hypertension in USA
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA